SQI | Jotup

Microchip Technology Expands Its Serial SRAM Portfolio to Larger Densities and Increased Speeds

Retrieved on:

Thursday, March 28, 2024

SRAM, SPI, MB, MCU, Microchip Technology, MCHP, RAM, SDI, SQI, Integrated circuit, Computer data storage

CHANDLER, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- To address a common customer need for bigger and faster SRAM, Microchip Technology (Nasdaq: MCHP) has expanded its Serial SRAM product line to include larger densities of up to 4 Mb and increased Serial Peripheral Interface/Serial Quad I/O™ Interface (SPI/SQI™) speed to 143 MHz.

Key Points:

CHANDLER, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- To address a common customer need for bigger and faster SRAM, Microchip Technology (Nasdaq: MCHP) has expanded its Serial SRAM product line to include larger densities of up to 4 Mb and increased Serial Peripheral Interface/Serial Quad I/O™ Interface (SPI/SQI™) speed to 143 MHz.
This reduces the need for a more expensive, high-pin-count MCU and can help minimize the overall board footprint.
The 2 Mb and 4 Mb serial SRAM devices are available starting at $1.60 each in 10,000-unit quantities.
For additional information and to purchase, contact a Microchip sales representative, authorized worldwide distributor or visit Microchip’s Purchasing and Client Services website, www.microchipdirect.com .

Mapping unmarked graves: Why the Mohawk Mothers are fighting McGill University

Retrieved on:

Thursday, September 28, 2023

The ruling comes after a group of Indigenous women known as the Mohawk Mothers called for an emergency court hearing to halt excavations at the site.

Key Points:

The ruling comes after a group of Indigenous women known as the Mohawk Mothers called for an emergency court hearing to halt excavations at the site.
In October 2022, the Mohawk Mothers obtained a temporary injunction against McGill to stop any excavations.
In April, Québec’s Superior Court approved a settlement allowing the Mohawk Mothers to investigate unmarked graves at the site.
Read more:
Inside the search for the unmarked graves of children lost to Indian Residential Schools — Podcast

Defining mapping

McGill’s lawyer argued that mapping means making a map with points or zones where different archaeological techniques should be applied to find human remains.
When all the zones were drawn, the panel could be disbanded because the mapping was over.
This interpretation distorts and extensively simplifies the process of mapping the unmarked graves of children.
It reduces mapping to a mere checklist item, detached from the ever-changing reality on the ground.
While this initial mapping serves as a starting point, the panel should remain involved as the map evolves.

Colonial vs. decolonial perspectives

Observing the courtroom proceedings, I was struck by the enduring presence of colonial assumptions about cartography.
Indigenous communities continue having to advocate for and defend their cartographic methods in order to uphold their connections and duties to the land.
A truly decolonial mapping project centres and respects Indigenous geographical knowledge and protocols, and includes involvement of Indigenous communities in the process.

SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing

Retrieved on:

Friday, June 16, 2023

TORONTO, June 16, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF) today announced that the Company's board of directors (the "Board") has received a notice of intention (the "Notice") to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership ("Pivot"), under Section 244(1) of the Bankruptcy and Insolvency Act (the "Act").

Key Points:

TORONTO, June 16, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF) today announced that the Company's board of directors (the "Board") has received a notice of intention (the "Notice") to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership ("Pivot"), under Section 244(1) of the Bankruptcy and Insolvency Act (the "Act").
As previously announced, there has been significant doubt about the Company's ability to continue as a going concern for several months.
As such, while the enforcement of the Notice is subject to a 10-day notice period, the Board has made the decision to consent to the early enforcement of security by Pivot.
The Company will proceed with a voluntary assignment in bankruptcy pursuant to the provisions of the Act and upon completion of the filing will announce that such filing is complete and that a trustee has been formally retained.

SQI Diagnostics Reports Internal Restructuring

Retrieved on:

Tuesday, June 6, 2023

Intellectual property, Negotiation, Science, SQI, Documentation, Bank statement, SEDAR, Bankruptcy, Legislation, Bank

SQI has provided similar notices to its staff to reduce its number of employees from approximately 20 full-time employees to 2 full-time employees.

Key Points:

SQI has provided similar notices to its staff to reduce its number of employees from approximately 20 full-time employees to 2 full-time employees.
Additional details regarding the Company's future direction and strategy will be announced in due course.
The Company's ability to continue as a going concern is dependent upon the Company's ability to raise additional capital through equity and/or debt financings and achieve profitable operations.
Failure to obtain sufficient capital by such date may result in the Company ceasing its operations and/or completing a filing under applicable bankruptcy and insolvency or restructuring legislation.

SQI Diagnostics Reports Second Quarter 2023 Results

Retrieved on:

Tuesday, May 30, 2023

Workforce, Bank statement, COVID-19, Negotiation, Quality, Science, SQI, Documentation, Acquisition, Corporation, Medicine, SEDAR, R, PCR, Cooperative federalism (economics), Pharmaceutical industry, Bank, Engineering

TORONTO, May 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022.

Key Points:

TORONTO, May 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022.
Corporate & General expenses were $1.0M in Q2 2023, compared to $2.4M in Q2 2022.
The R&D expense category, which includes Manufacturing, Quality and Engineering, was $0.4M in Q2 2023, compared to $2.8M in Q2 2022.
Net loss of $3.5M, or $0.01 per share, in Q2 2023, compared to a net loss of $2.6M, or $0.01 per share, in Q2 2022.

SQI to Focus on Development of Point of Care Products In Respiratory Health

Retrieved on:

Tuesday, March 28, 2023

Workforce, Partnership, SARS-CoV-2, Biomarker, Trial of the century, Science, Transplant, SQI, US, UHN, Patient, University Health Network, POC, Health, Medical device

TORONTO, March 28, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health, today announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care (POC) products in respiratory health.

Key Points:

TORONTO, March 28, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health, today announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care (POC) products in respiratory health.
The TORdx LUNG Test helps predict recipient outcome should the organ be transplanted.
SQI will be engaging with the US FDA and initiate clinical studies across four sites in North America to support regulatory approval for the product.
SQI's partnership with Owlstone Medical to develop non-invasive breath diagnostic products to monitor the health of lung transplant recipients.

SQI Diagnostics Announces New Capital Markets Consulting Agreement

Retrieved on:

Monday, March 13, 2023

Documentation, Looking Glass, Negotiation, Glass, Science, SQI, Pharmaceutical industry, Financial services

TORONTO, March 13, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants ("Looking Glass"), pursuant to which Looking Glass will assist the Company with identifying potential new sources of up to $10 million of equity financing.

Key Points:

TORONTO, March 13, 2023 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants ("Looking Glass"), pursuant to which Looking Glass will assist the Company with identifying potential new sources of up to $10 million of equity financing.
Michael Ciardi of Looking Glass, which has offices in New York and London, stated "I am very much impressed with the pipeline of products SQI has in development and is looking forward to the commercialization of these products to help save countless of lives in the respiratory health arena."
There can be no assurances as to whether Looking Glass will be successful in assisting the Company with any new financings nor can there be certainty with respect to the terms of any such new financing or financings.
The Company will announce additional details relating to any new financing or financings in due course in the event that it is successful in negotiating and entering into definitive documentation relating to same.

SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

Retrieved on:

Tuesday, January 31, 2023

TORONTO, Jan. 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

Key Points:

TORONTO, Jan. 30, 2023 /PRNewswire/ - SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.
"Last fiscal year we witnessed the transition of SQI from an R&D organization to a commercial company.
We earned record revenues of $8.1 million in fiscal 2022 up significantly from $0.9 million in fiscal 2021.
The increase in sales is attributed to the COVID-19 human testing business acquired during the second quarter of fiscal 2022.

EQS-News: DWS announces Strategic Ambition and Financial Targets for 2025

Retrieved on:

Sunday, December 18, 2022

In the Americas, DWS aims to grow Xtrackers and its Alternatives business and in Asia Pacific, the company wants to focus on strong strategic partnerships.

Key Points:

In the Americas, DWS aims to grow Xtrackers and its Alternatives business and in Asia Pacific, the company wants to focus on strong strategic partnerships.
We are committed to self-funding our changes by reallocating financial resources freed up by divestments, delayering and cost initiatives.
With our strategy we want to deliver a better DWS with ambitious financial targets, enhanced transparency and an attractive dividend pay-out policy.”
Hoops adds: “We remain fully committed to ESG.
To self-fund investments, DWS intends to reallocate financial resources from other parts of the business.

SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding

Retrieved on:

Thursday, November 10, 2022

Business, SQI, Informatics, Adoption, Technology, Municipal government in Canada, Federal Economic Development Agency for Southern Ontario, Company, Science, Growth, CEO, Agency, Oil, Facebook

By developing first-of-its-kind innovative medical technologies, SQI Diagnostics Inc. is harnessing the talent in the region and creating good local jobs."

Key Points:

By developing first-of-its-kind innovative medical technologies, SQI Diagnostics Inc. is harnessing the talent in the region and creating good local jobs."
SQI Diagnostics is driven to create and market life-saving testing technologies that help more people in more places live longer, healthier lives.
For 13 years, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada's most populous region.
Learn more about the impacts the Agency is having in southern Ontario by exploring our pivotal projects, our Southern Ontario Spotlight, and FedDev Ontario's Twitter, Facebook, Instagram and LinkedIn.